After 3 years of intensive research in collaboration with Nestlé Skin Health (Galderma), the Oroxcell team succeeded in developing a Cytokinesis-Block Micronucleus Assay using Episkin LM™ Reconstructed Human Epidermis (MN3D assay).
During the proof of concept testing the method achieved an excellent prediction accuracy of 80% with a set of substances containing progenotoxins known to require metabolic activation as well as standard positive and negative reference chemicals. The native physiological metabolic activity of the Episkin LM™ epidermis model ensures that progenotoxins are activated and detected.
The MN3D assay is now available at Oroxcell.
It shows outstanding promise to improve the evaluation of the widest range of substances, notably by direct detection of genotoxins and progenotoxins that are insoluble in the standard cell culturing buffers.
This work exemplifies Oroxcell’s commitment to and investment in alternative methods development and validation-in keeping with the principles of the EU Cosmetics Directive 7th Amendment and REACH regulations. It demonstrates our capacity to propose innovative in vitro assays for compound safety assessment to the dermo-cosmetics, household products and chemicals industries.
The MN3D method proof of concept paper was accepted for publication in the journal Mutation Research/ Genetic Toxicology and Environmental Mutagenesis.
Check out the article-in-press which was made available on-line on the 10th of March 2018
